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Abstract
Human β2-glycoprotein I (β2GPI) binds to recombinant hepatitis B surface antigen (rHBsAg), but the location of the binding domain on
β2GPI is unknown. It has been suggested that the lipid rather than the protein moiety of rHBsAg binds to β2GPI. Since β2GPI binds to anionic
phospholipids (PL) through its lipid-binding region in the fifth domain of β2GPI, we predicted that this lipid-binding region may also be involved
in binding rHBsAg. In this study, we examined rHBsAg binding to two naturally occurring mutants of β2GPI, Cys306Gly and Trp316Ser, or
evolutionarily conserved hydrophobic amino acid sequence, Leu313-Ala314-Phe315 in the fifth domain of β2GPI. The two naturally occurring
mutations and two mutagenized amino acids, Leu313Gly or Phe315Ser, disrupted the binding of recombinant β2GPI (rβ2GPI) to both rHBsAg
and cardiolipin (CL), an anionic PL. These results suggest that rHBsAg and CL share the same region in the fifth domain of β2GPI. Credence to
this conclusion was further provided by competitive ELISA, where CL-bound rβ2GPI was incubated with increasing amounts of rHBsAg. As
expected, pre-incubation of rβ2GPI with CL precluded binding to rHBsAg, indicating that CL and rHBsAg bind to the same region on β2GPI. Our
data provide evidence that the lipid (PL) rather than the protein moiety of rHBsAg binds to β2GPI and that this binding region is located in the
fifth domain of β2GPI, which also binds to anionic PL.
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Hepatitis B virus (HBV) belongs to a DNA-containing small
enveloped hepadanavirus family, which includes woodchuck
hepatitis virus [1], ground squirrel hepatitis virus [2], duck
hepatitis B virus [3], and heron hepatitis virus [4]. These viruses
infect and replicate primarily in hepatocytes in vivo and often
lead to chronic infection in the cells of their respective hosts
[5]. However, the mode of entry for HBV into the humanAbbreviations: HBV, Hepatitis B virus; HBsAg, Hepatitis B surface antigen;
r, Recombinant; PL, Phospholipid; β2GPI, β2-Glycoprotein I; apoH, Apolipo-
protein H; APA, Antiphospholipid antibodies; CL, Cardiolipin
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doi:10.1016/j.bbadis.2008.01.001hepatocytes or the HBV receptor is not well established. Several
potential candidates for HBV receptor have been reported,
including a 50 kDa glycoprotein known as β2-glycoprotein I
(β2GPI) [6,7]. β2GPI, also known as apolipoprotein H, is a
plasma glycoprotein [8], which is associated with very low-
density lipoproteins (VLDL), high-density lipoproteins (HDL),
low-density lipoprotein (LDL) and chylomicrons, and it also
exists in lipid-free form in plasma [9,10]. Furthermore, β2GPI
shows higher binding with oxidized LDL than native LDL [11–
13]. Mature β2GPI is a single chain polypeptide of 326 amino
acids [14–17] and belongs to the short consensus repeats (SCR)
or complement control protein (CCP) superfamily consisting of
five homologous repeats (∼60 amino acids each) referred to as:
GP-I domains, Sushi domains, SCRs or SSP repeats. There are
22 cysteine residues in human β2GPI, which are conserved in
bovine, rat, mouse and dog [18–21]. The first four GP-I domains
(∼60 amino acids each) are structurally related, while the fifth
domain (84 amino acids) is the most variable and includes a
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hydrophobic amino acids (313–316), and three disulfide bonds
instead of two as in each of the preceding four domains.
Previously, we demonstrated that the β2GPI cDNA transfected
COS-1 cells expressed and secreted full-length recombinant
β2GPI (rβ2GPI) into its culture medium that exhibits normal
binding to recombinant hepatitis B surface antigen (rHBsAg)
[6]. We have also demonstrated that carbohydrate side chains
and arginine residues of β2GPI have no effect on its ability to
bind to rHBsAg, but this binding was disrupted by the reduction
of disulfide bonds and by the chemical modification of as few as
three lysine residues [7]. Since the fifth domain of β2GPI has a
cluster of lysine residues (282–287) and three disulfide bonds, it
was predicted to contain the binding site for rHBsAg.
Using either artificial mixtures of lipids [10] or pure lipids [22]
it was originally suggested that ionic and hydrophobic interac-
tions play major roles in the binding of β2GPI with phospholi-
pids (PL). The binding of β2GPI with anionic PL triggers the
production of a subset antiphospholipid antibodies (APA) in
autoimmune diseases [23,24]. Several natural mutations have
been reported in the β2GPI gene, including Ser88Asn, Val247-
Leu, Cys306Gly, and Trp316Ser [25–27]. The two mutations in
the fifth domain of β2GPI, Cys306Gly and Trp316Ser, may be
important because Cys306Gly disrupts one of the disulfide bonds
and Trp316Ser disrupts the integrity of a cluster of hydrophobic
amino acids at positions 313–316 (Leu-Ala-Phe-Trp), which are
evolutionarily conserved in bovine, rat, mouse, dog, and human
β2GPI [18–21]. Previously, we demonstrated that the Cys306Gly
and Trp316Ser mutations disrupt the binding of plasma β2GPI
[27] and rβ2GPI [28] to anionic PL. By site-directed mutagenesis,
we have also shown that in addition to Trp316, Leu313 and
Phe315 are required for rβ2GPI–PL-binding [28].
Since the binding of β2GPI to rHBsAg is also dependent on
the integrity of disulfide bond(s) and some lysine residues whose
locations are not known [6,7], we hypothesized that rHBsAg
would bind to the same region in the fifth domain of β2GPI that
is involved in binding anionic PL. To examine this hypothesis,
we mutagenized the fifth domain of β2GPI and determined the
effect of these mutations on its ability to bind rHBsAg compared
to PL. We also performed a competition assay in an attempt
to discriminate between the binding of rHBsAg and anionic
PL to rβ2GPI. Our results show that rHBsAg and anionic PL
compete for the same binding region on rβ2GPI.
2. Materials and methods
2.1. Site-directed mutagenesis
Previously described cloned β2GPI cDNA in eukaryotic expression vector
(pRc/CMV, Invitrogen) [16] was used to create the desired mutations using the
QuickChange Site-Directed Mutagenesis kit (Strategene) as described earlier
[28]. Briefly, two mutagenic primers containing the desired mutation in the
middle were used to PCR amplify the entire recombinant plasmid with PfuDNA
polymerase to mutate the β2GPI cDNA. For each mutagenesis experiments, four
to eight colonies were grown in 5 ml of LB media containing ampicillin at 37 °C
for 16 h. The plasmid DNA was extracted by the Spin Plasmid Miniprep kit
(Qiagen) and sequenced by chain-termination dideoxynucleosides methods [29]
using Sequenase Version 2.0 DNA Sequencing kit (United States Biochemical)
to confirm the mutation as well as the fidelity of Pfu DNA polymerase.2.2. Transient expression of rβ2GPI
COS-1 cells were maintained as a monolayer in Dulbecco's Modified Eagle
Medium (DMEM) (Gibco-BRL) supplemented with 10% fetal bovine serum
(FBS) (HyClone), 2 mM glutamine, 100 U/ml penicillin, and 100 μg/ml strep-
tomycin at 37 °C under 5% CO2. Subconfluent monolayer of the cells grown
overnight in 60 mm dishes was transiently transfected with wild-type and
mutant-type β2GPI cDNA by DEAE-dextran method as described earlier
[28,30]. After 48 h of transfection, cells were washed twice with phosphate-
buffer-saline (PBS) and incubated for an additional 4–12 h in serum-free culture
media to collect the secreted rβ2GPI.
2.3. Detection of rβ2GPI by capture ELISA
The rβ2GPl levels were detected by modified capture ELISA [6]. Briefly,
50 μl of anti-β2GPI monoclonal antibody (mAb) (Chemicon International, Inc.)
(5–7 μg/ml in PBS) was adsorbed onto 96 well vinyl microtiter plates (Costar)
by overnight incubation at 4 °C with a cover to prevent evaporation. The wells
were washed three times with PBS and blocked with PBS containing 1% bovine
serum albumin (BSA) at 37 °C for 90 min. Fifty μI of serum-free–cell-free
culture media from the transfected COS-1 cells containing rβ2GPI was added to
the mAb-coated wells in triplicate followed by polyclonal rabbit anti-β2GPI
antiserum (Alexis Corp.) (0.5 μg/ml in PBS containing 1% BSA) and then by
alkaline phosphatase-conjugated goat anti-rabbit IgG antiserum (Instar Corp.).
Each reaction was incubated at 37 °C for 90 min followed by addition of 100 μI
of para-nitrophenyl phosphate (PNP) substrate (Chemicon International, Inc.).
The wells were washed three times with PBS between each incubation for all
binding assays. The color intensity was measured as optical density (OD) at
410 nm after different time intervals.
2.4. Binding of rβ2GPI to rHBsAg
The rβ2GPI captured on anti-β2GPI mAb-coated wells was incubated with
2.5 μg of rHBsAg (rS,L⁎ particles were produced in Saccharomyces cerevisiae
[31,32]) diluted in PBS containing 1% BSA at 22 °C for 16 h [6]. The bound
rHBsAg was then detected by goat anti-hepatitis B surface antigen (anti-HBs)
antiserum (OAKO Corp.) followed by alkaline phosphatase-conjugated rabbit
anti-goat IgG antiserum (Instar Corp.). Each reaction was incubated at 37 °C for
90 min followed by addition of 100 μI of PNP. The wells were washed three
times with PBS between each incubation for all binding assays. The color
intensity was measured as optical density (OD) at 410 nm after different time
intervals.
2.5. Binding of rβ2GPI to cardiolipin (CL)
The binding of rβ2GPI to CL was performed by CL-ELISA as previously
described [28]. Briefly, 96 well vinyl microtiter plates (Costar) were coated with
30 μI of CL solution in ethanol (50 μg/ml) (Sigma). The plates were dried under
vacuum and blocked with PBS containing 1%milk and 0.3% gelatin at 25 °C for
1 h. The plates were washed three times with PBS and incubated with 50 μI of
serum-free–cell-free culture media of transfected COS-1 cells containing
rβ2GPI at 25 °C for 3 h. The bound rβ2GPI was detected by polyclonal rabbit
anti-β2GPI antiserum (Alexis Corp.) (0.5 μg/ml in PBS containing 1% BSA)
followed by alkaline phosphatase-conjugated goat anti-rabbit IgG antiserum
(Instar Corp.). Each reaction was incubated at 37 °C for 90 min followed by
addition of 100 μI of PNP. The color intensity was measured as optical density
(OD) at 410 nm after different time intervals.
2.6. Competition assays
A competition assay was performed in which CL-coated microtiter wells
were incubatedwith 50 μI of serum-free–cell-free culturemedia from transfected
COS-1 cells containing rβ2GPI at 25 °C for 3 h followed by three washings with
PBS. TheCL-bound rβ2GPIwas then allowed to bind to the increasing amount of
rHBsAg (rS,L⁎ particles, 0.31 to 10 μg/well diluted in PBS containing 1% BSA)
and the bound rHBsAg was detected by anti-HBs antiserum (DAKO Corp.) as
described above. Control wells received no rHBsAg. The CL-bound rβ2GPI was
Fig. 1. Effect of naturally occurring missense mutations in the fifth domain of β2GPI (Cys306Gly and Trp316Ser) on its ability to bind to rHBsAg and CL. The rβ2GPI
secreted into the culture medium of mock, wild-type, Gly306 mutant, Ser316 mutant and Gly306/Ser316 double mutant transfected COS-1 cells was quantitated by
capture ELISA (n). The secreted wild-type and mutant-type rβ2GPI were then allowed to bind to rHBsAg ( ) or CL ( ) on microtiter plates to examine the effect of
these mutations on the ability of rβ2GPI to bind to rHBsAg or CL. Results are given as mean±SD from three independent clones in triplicate (n=9).
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control assay was also performed where rβ2GPI captured by anti-β2GPI mAb-
coatedmicrotiter wells was allowed to bind to increasing amounts of rHBsAg (rS,
L⁎ particles, 0.31 to 10 μg/well diluted in PBS containing 1% BSA) and the
bound rHBsAg was detected by anti-HBs antiserum, as described above.3. Results
3.1. Effect of the Cys306Gly and Trp316Ser mutations on
rHBsAg binding
Fig. 1 shows the secreted levels of wild-type and mutant
rβ2GPI into the serum-free–cell-free culture media of the
transfected COS-1 cells and the binding of rβ2GPI wild- and
mutant-types to rHBsAg or CL. While the levels of wild-type
and mutant rβ2GPI secreted into the culture media wereFig. 2. Effect of hydrophobic amino acids in the fifth domain of rβ2GPI at positions 31
positions 313–316 were mutated to neutral amino acids (Trp316Ser, Phe315Ser, Ala3
were quantitated by capture ELISA (n) followed by their binding to rHBsAg ( )
triplicate (n=9).comparable (solid bars), the binding of rβ2GPI mutants
(Gly306, Ser316, and Gly306/Ser316) to rHBsAg was sig-
nificantly reduced as compared to the wild-type rβ2GPI (dark
bars). The isoform-specific binding of rβ2GPI with rHBsAg
(dark bars) was similar to that observed for the CL–rβ2GPI
binding (light bars). These results show that a single mutation
either at codon 306 or 316 in the fifth domain of β2GPI is
sufficient to disrupt the interaction of rβ2GPI with either
rHBsAg or CL.
3.2. Effect of hydrophobic amino acids at positions 313–316 on
rHBsAg binding
In addition to the naturally occurring Trp316Ser mutation,
we changed the remaining three conserved hydrophobic amino
acids at positions 313–315 to neutral amino acids (Leu313Gly,3–316 on its ability to bind to rHBsAg and CL. Four hydrophobic amino acids at
14Ser and Leu313Gly) and expressed in COS-1 cells. The secreted rβ2GPI forms
or CL ( ). Results are given as mean±SD from three independent clones in
Fig. 3. Competition assay. (A) Microtiter wells coated with CL were allowed to bind to rβ2GPI and then incubated for 16 h with increasing amount of rHBsAg.
(B) Microtiter wells coated with anti-β2GPI were allowed to bind to rβ2GPI followed by binding to increasing amount of rHBsAg. Results are given as mean±SD
from three independent experiments in triplicate (n=9).
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mutagenesis, expressed them in COS-1 cells, and examined the
binding of the mutant-type rβ2GPI with rHBsAg or CL (Fig. 2).
While Ala314Ser had no effect on the binding of rβ2GPI
with rHBsAg (92%; dark bars) or CL (106%; light bars), the
Leu313Gly and Phe315Ser mutations significantly reduced
the binding of mutant rβ2GPI with rHBsAg (38% and 9% of
the wild-type rβ2GPI, respectively; dark bars) as well as with
CL (25% and 13% of the wild-type rβ2GPI, respectively; light
bars). However, the levels of rβ2GPI secreted into the serum-
free–cell-free culture media of the wild-type and each mutant
β2GPI cDNA transfected COS-1 cells were comparable (solid
bars). The results from these experiments further demonstrate
that rHBsAg and CL share the same binding region on the
β2GPI molecules.
3.3. Competition between rHBsAg and CL for binding to β2GPI
To confirm our findings that rHBsAg and CL bind to the
same region on β2GPI, we performed two competition assays.
In the first assay, CL-bound rβ2GPI on microtiter wells was
allowed to bind with an increasing amount of rHBsAg (0.31 to10 μg/well) (Fig. 3A). As expected, CL-bound rβ2GPI exhi-
bited no binding with rHBsAg, as the binding site for rHBsAg
on β2GPI was blocked by CL. These results suggest that the
binding of rB2GPI to CL is saturated with higher affinity than
with rHBsAg because the addition of increasing amounts of
rHBsAg did not affect rβ2GPI–CL binding. A second assay was
designed to test whether steric hindrance or steric resistance
is the reason for lack of binding of rHBsAg to rβ2GPI–CL
complex. In this experiment, rβ2GPI captured by anti-β2GPI
mAb on microtiter wells was incubated with increasing amounts
of rHBsAg (Fig. 3B). The rHBsAg binding to the mAb-cap-
tured rβ2GPI increased with increasing amount of rHBsAg
added (Fig. 3B) as opposed to CL-bound rβ2GPI, which de-
monstrated no binding to rHBsAg even at the highest con-
centration (Fig. 3A). This suggests that the binding sites for
rHBsAg (or CL) and mAb on β2GPI are different and thus steric
hindrance caused by the mAb is not a factor.
4. Discussion
The mechanism of HBV entry and its cellular receptor on
the surface of human hepatocytes are not well understood.
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includes β2GPI, which was first reported by us [6,7] and later by
others [33–35]. β2GPI is a secretary glycoprotein that is present
in plasma in association with several lipoprotein particles as
well as in lipid-free form [9,10,22]. Since β2GPI is not a
transmembrane protein, a typical criterion for a viral receptor,
we have earlier hypothesized that β2GPI present on the surface
of lipoprotein particles might serve as a receptor for HBV and
that the lipoprotein–HBV complex enters hepatocytes during
the process of lipoprotein uptakes [6]. Although the experi-
mental data supporting this hypothesis is lacking at present, here
we have addressed several critical questions regarding the
interaction between β2GPI and HBV.
Previously, we demonstrated that the binding of β2GPI with
rHBsAg was disrupted by reducing the intramolecular disulfide
bonds of β2GPI [6] and chemical modification of as few as
three positively charged lysine residues of β2GPI [7]. However,
this interaction was not affected by the removal of β2GPI
carbohydrate side chains or chemical modification of arginine,
the other positively charged amino acid [7]. These results
suggested that the interaction between β2GPI and rHBsAg was
most likely due to protein–protein interaction. On the other
hand, Neurath and Strick [36] have suggested that since
delipidation of rHBsAg abolishes β2GP1–rHBsAg binding,
that the lipid moiety of rHBsAg is involved in binding β2GPI.
Subsequently, Stefas et al. [35] have demonstrated that the
myristylated pre-S1 domain of HBsAg strongly interacted with
β2GPI, which involved PL component of HBV envelope be-
cause the removal of PL component by detergent or oxi-
dation prevented β2GPI–HBsAg interaction. Notwithstanding
whether it is the lipid or protein moiety of rHBsAg that binds to
β2GPI, the β2GPI domain that binds to rHBsAg is not known.
A robust way to localize the binding domain of β2GPI is
to assess the role of naturally occurring or artificially created
missense mutations of β2GPI in binding rHBsAg. We identified
two naturally occurring missense mutations, Cys306Gly and
Trp316Ser in the fifth domain of β2GPI that disrupt PL-binding
to β2GPI [27,28]. The Cys306Gly mutation disrupts a disulfide
bond between Cys306 and Cys281, which is critical for clus-
tering several lysine residues [15]. The Trp316Ser mutation
disrupts the integrity of an evolutionarily conserved hydro-
phobic amino acid sequence at positions 313–316 [15]. We
hypothesized that these mutations would also disrupt β2GPI–
rHBsAg binding. Indeed our data demonstrate that the mu-
tant rβ2GPI carrying one or both mutations does not bind to
rHBsAg. These results show that rHBsAg and anionic PL share
the same binding region on the β2GPI molecule. To further
identify or discriminate between the binding sites of rHBsAg
and anionic PL on β2GPI, we examined the effect of the
remaining evolutionarily conserved hydrophobic amino acids
in the vicinity of the Trp316Ser mutation at positions 313–315
on the ability of β2GPI to bind rHBsAg. Three hydrophobic
amino acids at positions 313–315 were mutated to neutral
residues (Leu313Gly, Ala314Ser and Phe315Ser) and the
mutant rβ2GPI was then allowed to bind rHBsAg or CL. The
Leu313Gly and Phe315Ser mutations significantly reduced
the binding of mutant rβ2GPI to both rHBsAg and CL, whilethe Ala314Ser mutation showed normal binding with both
rHBsAg and CL. These results indicate that the binding of
β2GPI to rHBsAg or CL involves both ionic (shown by the
Cys306Gly mutation, which disrupts the clustering of lysine
residues of the fifth domain) and hydrophobic (shown by the
mutagenized 313–316 sequence) interactions.
Further evidence that rHBsAg and CL share a binding region
on β2GPI comes from our competition assay in which rβ2GPI
bound to CL-coated microtiter wells was allowed to bind to
increasing amounts of rHBsAg. If CL and rHBsAg share the
same binding region on rβ2GPI then CL-bound rβ2GPI would
not be able to bind rHBsAg. Indeed, we found that rβ2GPI
bound to CL was unable to bind rHBsAg. This suggests that
rHBsAg and CL compete for the same binding region on
rβ2GPI. Although it is possible that the rβ2GPI bound to the
well via CLmight be in the correct orientation to bind to rHBsAg
if the two binding regions on rβ2GPI were different as in case of
anti-β2GPI antibodies (the mAb) which did bind to CL-bound
rβ2GPI.
Our results on rHBsAg binding with β2GPI using the na-
turally occurring mutations as well as artificially created mu-
tations in the lipid-binding region of β2GPI suggest that the lipid
(PL) rather than the protein moiety of rHBsAg binds to rβ2GPI,
as originally suggested by Neurath and Strick [36] and later by
Stefas et al. [35]. The Cys306Gly mutation in the fifth domain
of β2GPI disrupts the clustering of lysine residues, which are
required for ionic binding with PL. Likewise, the fifth domain is
necessary for the hydrophobic binding with PL [37–39]. Since
mutations at this region also disrupt the binding of β2GPI with
rHBsAg, it appears that the lipid moiety, perhaps anionic PL,
rather than the protein moiety of rHBsAg, is involved in binding
with β2GPI. Indirect support to the hypothesis that the lipid
moiety of rHBsAg binds to the lipid-binding region in the fifth
domain of β2GPI comes from another competition assay where
the rβ2GPI captured by anti-β2GPI mAb on coated microtiter
wells was able to bind to rHBsAg. This indicates that while the
lipid moiety of rHBsAg binds to the lipid-binding region in the
fifth domain of β2GPI, the commercially available anti-β2GPI
mAb binds to a different domain of β2GPI but the rβ2GPI–CL
complex could not bind rHBsAg confirming that the CL and
rHBsAg bind to the same region on rβ2GPI.
In summary, we have identified the binding region for rHBsAg
on β2GPI, which is located in the fifth domain of β2GPI and
it appears to be the same as PL-binding region on β2GPI. Our
results in conjunction with the observation of Neurath and Strick
[36] and Stefas et al. [35] indicate that rHBsAg binds to β2GPI
through its lipid moiety. These results also confirm our previous
reports that the interaction between rHBsAg and β2GPI is strong
and saturable [6,7].
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